Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Dr. Jack Antel, a world-renowned multiple sclerosis expert, as clinical advisor for its MS program focused on Lucid-21-302 (Lucid-MS). Dr. Antel will advise on the clinical development and efficacy trial design for Lucid-MS, a patented investigational drug designed to inhibit demyelination in MS.
Dr. Antel brings significant expertise as a Professor of Neurology at McGill University and former National Scientific Director of the endMS Research and Training Network. He has published over 450 scientific articles and held prestigious positions including Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada and President of ACTRIMS.
He will join existing advisor Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, to support Quantum's development of Lucid-MS toward Phase 2 clinical trials.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato la nomina del Dr. Jack Antel, noto esperto mondiale di sclerosi multipla, come consulente clinico per il suo programma MS focalizzato su Lucid-21-302 (Lucid-MS). Il Dr. Antel fornirà consulenza sullo sviluppo clinico e sulla progettazione degli studi di efficacia per Lucid-MS, un farmaco sperimentale brevettato progettato per inibire la demielinizzazione nella SM.
Il Dr. Antel porta una notevole expertise come Professore di Neurologia presso la McGill University e ex Direttore Scientifico Nazionale della rete di Ricerca e Formazione endMS. Ha pubblicato oltre 450 articoli scientifici ed ha ricoperto ruoli prestigiosi, tra cui Presidente del Medical Advisory Board della Multiple Sclerosis Society of Canada e Presidente di ACTRIMS.
Si unirà all'attuale consulente Dr. Peter Stys, Professore di Neuroscienze all'Università di Calgary, per sostenere lo sviluppo di Lucid-MS verso Phase 2 clinical trials.
Quantum BioPharma (NASDAQ: QNTM) ha anunciado la designación del Dr. Jack Antel, un reconocido experto mundial en esclerosis múltiple, como asesor clínico de su programa de EM centrado en Lucid-21-302 (Lucid-MS). El Dr. Antel asesorará en el desarrollo clínico y en el diseño de ensayos de eficacia para Lucid-MS, un fármaco en investigación con patente diseñado para inhibir la desmielinización en la EM.
El Dr. Antel aporta una notable experiencia como Profesor de Neurología en la Universidad McGill y ex Director Científico Nacional de la red de Investigación y Formación endMS. Ha publicado más de 450 artículos científicos y ha ocupado cargos prestigiosos, como Presidente de la Junta Médica Asesora de la Sociedad de Esclerosis Múltiple de Canadá y Presidente de ACTRIMS.
Se unirá al actual asesor Dr. Peter Stys, Profesor de Neurociencias en la Universidad de Calgary, para apoyar el desarrollo de Lucid-MS hacia Phase 2 clinical trials.
Quantum BioPharma(NASDAQ: QNTM)가 세계적으로 유명한 Dr. Jack Antel를 MS 프로그램의 임상 고문으로 임명했다. Lucid-21-302(Lucid-MS)에 초점을 맞춘 프로그램이다. Dr. Antel은 Lucid-MS의 임상 개발과 효능 시험 설계에 자문을 제공하며, 이 약물은 다발성 경화증에서 탈髓화를 억제하도록 설계된 특허받은 연구 약물이다.
Antel 박사는 맥길 대학교 신경학 교수이자 endMS 연구 및 훈련 네트워크의 전 국가 과학 이사로서 상당한 전문 지식을 제공합니다. 그는 450개의 과학 논문을 게재했으며, 캐나다 다발성 경화증 협회의 의학 자문위원회 의장과 ACTRIMS의 회장을 비롯한 명예로운 직책을 역임했습니다.
그는 현 자문 Dr. Peter Stys(캘거리 대학교 신경과학 교수)와 합류하여 Lucid-MS를 Phase 2 clinical trials로의 개발을 지원할 것입니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé la nomination du Dr Jack Antel, expert mondial renommé en sclérose en plaques, en tant que conseiller clinique pour son programme MS axé sur Lucid-21-302 (Lucid-MS). Le Dr Antel conseillera sur le développement clinique et la conception des essais d’efficacité pour Lucid-MS, un médicament expérimental breveté conçu pour inhiber la démyélinisation dans la SEP.
Le Dr Antel apporte une expertise significative en tant que Professeur de neurologie à l'Université McGill et ancien Directeur scientifique national du réseau endMS de recherche et de formation. Il a publié plus de 450 articles scientifiques et a occupé des postes prestigieux, notamment président du Medical Advisory Board de la Société canadienne de la sclérose en plaques et président de ACTRIMS.
Il se joindra au conseiller actuel Dr Peter Stys, Professeur de neurosciences à l'Université de Calgary, pour soutenir le développement de Lucid-MS vers Phase 2 clinical trials.
Quantum BioPharma (NASDAQ: QNTM) hat die Ernennung von Dr. Jack Antel, einem weltweit renommierten Experten für Multiple Sklerose, als klinischen Berater für sein MS-Programm bekannt gegeben, das sich auf Lucid-21-302 (Lucid-MS) konzentriert. Dr. Antel wird Beratung zur klinischen Entwicklung und zur Gestaltung von Wirksamkeitsstudien für Lucid-MS leisten, einem patentierten investigativen Medikament, das darauf abzielt, die Demyelinisierung bei MS zu hemmen.
Dr. Antel bringt umfangreiche Expertise als Neurologie-Professor an der McGill University und ehemaliger National Scientific Director des endMS Forschungs- und Trainingsnetzwerks mit. Er hat über 450 wissenschaftliche Artikel veröffentlicht und hatte angesehene Positionen, darunter Vorsitzender des Medical Advisory Board der Multiple Sclerosis Society of Canada und Präsident von ACTRIMS.
Er wird sich dem bestehenden Berater Dr. Peter Stys, Professor für Neurowissenschaften an der University of Calgary, anschließen, um Quantum bei der Entwicklung von Lucid-MS in Richtung Phase 2 clinical trials zu unterstützen.
أعلنت Quantum BioPharma (بورصة ناسداك: QNTM) عن تعيين الدكتور جاك أنتِل، وهو خبير عالمي مشهور في التصلب المتعدد، كمستشار سريري لبرنامجها الخاص بالتصلب المتعدد الذي يركز على Lucid-21-302 (Lucid-MS). سيقدم الدكتور أنتل المشورة بشأن التطوير السريري وتصميم تجارب الفعالية لـ Lucid-MS، وهو دواء تجريبي مسجّل ببراءة اختراع صمّم ليعوق فقد الميلين في التصلب المتعدد.
يجلب الدكتور أنتِل خبرة كبيرة كأستاذ أعصاب في جامعة مكغيل وكنسخة المدير الوطني العلمي لشبكة endMS للبحوث والتدريب. لقد نشر أكثر من 450 مقالة علمية وتولى مناصب مرموقة بما في ذلك رئاسة المجلس الطبي الاستشاري لجمعية التصلب المتعدد في كندا ورئاسة ACTRIMS.
سيلتحق بالمتعاون الحالي الدكتور بيتر ستيس، أستاذ علوم الأعصاب في جامعة كالgary، لدعم تطوير Lucid-MS نحو Phase 2 clinical trials.
Quantum BioPharma（纳斯达克代码：QNTM） 已宣布任命 Dr. Jack Antel，世界知名的多发性硬化症专家，担任其以 Lucid-21-302（Lucid-MS）为重点的 MS 项目临床顾问。Antel 博士将就 Lucid-MS 的临床开发与疗效试验设计提供意见，这是一种专利的研究药物，旨在抑制多发性硬化中的髓鞘脱失。
Antel 博士以麦吉尔大学神经学教授身份以及前国家级 endMS 研究与培训网络总科学主管的身份，带来丰富经验。他已发表超过 450 篇科学论文，并担任加拿大多发性硬化协会医学顾问委员会主席以及 ACTRIMS 主席等荣誉职务。
他将与现任顾问 Dr. Peter Stys（卡尔加里大学神经科学教授）一道，支持 Quantum 将 Lucid-MS 推进至 Phase 2 clinical trials。
- Appointment of world-renowned MS expert Dr. Jack Antel strengthens clinical advisory team
- Progress toward Phase 2 clinical trials for Lucid-MS drug candidate
- Addition of expertise from a leading researcher with over 450 published scientific articles
- None.
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, welcomes Dr. Jack Antel as new clinical advisor to its multiple sclerosis (MS) program centered around Lucid-21-302 (“Lucid-MS”), a patented, new chemical entity investigational drug designed to inhibit demyelination in MS. Dr Antel will be advising Quantum Biopharma on the clinical development of Lucid-MS including design of efficacy trials of Lucid-MS in people with MS.
Dr. Antel is a clinical neurologist who is a world-renowned expert in MS. He is a Professor of Neurology at McGill University where he has served as Chairman of the Department of Neurology and Neurosurgery. From 2007-2015 he was the National Scientific Director of the endMS Research and Training Network supported by the MS Society of Canada. Dr. Antel has previously served as Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada, President of the International Society of Neuroimmunology and President of ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis). He has published over 450 articles in scientific journals with a research focus on mechanisms of tissue injury and repair in MS. In 2005, Dr. Antel was the recipient of the Dystel Award from the National Multiple Sclerosis Society and the American Academy of Neurology.
Dr. Antel will be joining Dr. Peter Stys who will continue as a clinical advisor to Quantum. Dr. Stys is a leading clinical neurologist and Professor of Neurosciences at the University of Calgary and has been a key advisor to Quantum BioPharma’s discovery and development team for several years.
“We are excited that Dr. Antel will be joining Quantum as a new clinical advisor. He brings a wealth of knowledge on MS that will be instrumental in advancing Lucid-MS into a Phase 2 clinical trial looking for an efficacy signal in people with MS,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
“Dr. Jack Antel is among the giants worldwide in the field of multiple sclerosis clinical and basic research. I am honored that he joined our Quantum team to support the clinical development program in MS. We are grateful for his enthusiastic involvement and advice for the development of Lucid-MS,” said Prof. Lakshmi P. Kotra, a director at Quantum BioPharma, a professor of medicinal chemistry at University of Toronto and a senior scientist at the Krembil Research Institute, University Health Network.
Dr. Jack Antel, M.D.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8af4e730-c265-4e3d-b84d-9e8530e5a12a
FAQ
Who is Dr. Jack Antel and what is his new role at Quantum BioPharma (QNTM)?
What is Lucid-MS (Lucid-21-302) being developed by Quantum BioPharma?
What are Dr. Jack Antel's credentials in multiple sclerosis research?
What stage of development is Quantum BioPharma's Lucid-MS treatment in?
Who are the key clinical advisors for Quantum BioPharma's MS program?
